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Introduction Certain psychedelic substances (e.g., LSD, psilocybin) have been tested more frequently for therapeutic 
applications. 
Emerging research suggests potential therapeutic benefits 
of psychedelic assisted therapy:
● Psychedelic assisted therapy: therapist guided 
process under a specific substance (e.g., LSD, 
psilocybin, ibogaine, MDMA) over a few sessions 
which vary in amount of sessions dependant on the 
psychedelic, which also include non-drug sessions 
before and after the experience. (Schenberg, 2018)
● Psychedelics are serotonergic agonist compounds 
that occasion an altered state of consciousness. 
Certain psychedelics are classified as classical 
psychedelics such as LSD, psilocybin, mescaline, 
and DMT, and other psychedelic substances like 
MDMA can be considered non-classical 
psychedelics.(Mithoefer et al., 2019)
Introduction Cont. Background Information:
● In order for a psychedelic compound to be 
deemed a safe substance for the public by the 
FDA(Food and Drug Administration), three 
phases of trials need to be fulfilled that 
demonstrate the efficacy of the drug.
● While there are several phase two pooled trial 
analysis for several different compounds of 
psychedelics, there is not a sufficient amount of 
research pertaining to recreational use of 
psychedelics.
● Keeping in mind that these clinical results are 
highly encouraging and significant, we need to 
investigate how people use psychedelic drugs 
under a recreational setting.
Present Study The present study used a dataset collected from a sample of undergraduate students that completed an 
assessment evaluating drug and alcohol use and 
mental health variables with a restricted focus to 
individuals who reported drug use (i.e., drugs and 
alcohol). 
Comparisons: 
● 38 participants endorsed prior use of 
psychedelics. These participants were 
compared to recreational drug/alcohol users 
that do not endorse psychedelic use. This group 
was comprised of 50 participants that were 
matched on age, sex, and ethnicity. 
● Group comparisons examine differences 
between stress, depression, anxiety.
Present Study Hypothesis: 
● Psychedelic group showing a significant difference in 
age, stress, and GPA as well as lower levels of 
depression and anxiety compared to the Recreational 
group.
Measures:
● Depression and Anxiety Stress Scale(DASS-21; Lovibond 
& Lovibond, 1995) 
○ 21 item self report measure assessing depression, anxiety, 
and stress.
● The Cannabis Use Disorders Identification Test-Revised 
(CUDIT-R; Adamson et al., 2010)
○ 8 item screening tool that assesses cannabis use and 
related problems associated with cannabis use.
● Alcohol Use Disorders Identification Test (AUDIT; 
Fleming et al., 1991)
○ 10 item screening tool used to assess drinking behaviors, 
alcohol consumption, and alcohol related problems. 
● The RT-18 Risk Taking Questionnaire (RT-18; de Haan et 
al., 2011)
○ A self-report screening tool assessing  risk-taking behavior 










Race Asian/asian american: 5.3% (2)
Black or african american: 2.6% (1)
Hispanic or latino: 10.5% (4)
White: 76.3% (29)
Other: 5.3% (2)
Asian/asian american: 6% (3)
Black or african american: 4% (2)


























CUDIT-TOTAL m=11.970 SD:7.659 m=2.640 SD:3.613 t(41.504)= 6.535, p<.001
AUDIT-TOTAL m=9.932 SD:7.603 m=7.620 SD:4.485 t(48.632)= 1.595, p=.117
Total Risk Taking Behavior m=5.784 SD:2.658 m=4.602 SD:2.683 t(78.056)= 2.033, p=.045
Total Risk Assessment m=3.919 SD:2.241 m=2.979 SD:1.831 t(68.419)= 2.079, p=.041
Results Overview ● No significant statistical differences were observed in variables between the Psychedelic 
and Recreational groups on age, stress, or GPA.
● No Significant statistical differences were 
observed between the Psychedelic and 
Recreational groups on alcohol consumption or 
stress.
● The Psychedelic group showed significantly 
higher levels of cannabis usage, depression and 
anxiety (p < .05).
Discussion &
Im p lica t ion s
Result Inferences:
● According to the results from this study, 
polysubstance abuse of psychedelics with other 
drugs may lead to worse outcomes. However, 
these are polysubstance users, therefore no 
signs of intention or motives can be evaluated 
for psychedelic use.
● These results are correlational, and do not 
suggest causation.
Future Research:
● More research would be required on people 
using psychedelics only in a recreational 
setting.
● Motives for psychedelic use could also be 
assessed in order to solidify for accurate 
interpretations of the data.
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